Pharma packaging companies commit to supply for COVID-19 fight
Stevanato Group, SCHOTT, and Gerresheimer confirm their readiness to support future COVID-19 vaccine with pharmaceutical containers.
The CEOs of Gerresheimer, Stevanato Group, and SCHOTT have pledged to ensure the ample supply of pharmaceutical containers for any future COVID-19 vaccine and treatment, the pharmaceutical packaging firms said on Tuesday.
The companies have also stated that they will make every effort to support the pharma industry’s priorities for overall medication supply in addition to COVID-19 drugs.
Each of the three companies manufactures billions of type-1 borosilicate glass vials - the most proven and widely available material used to store and deliver vaccines around the world.
According to Dr Frank Heinricht, Chairman of SCHOTT’s Management Board, 50 billion borosilicate glass containers are already deployed each year for a wide variety of vaccines and treatments. That fact, coupled with the significant investments to expand capacity, makes SCHOTT "optimistic" that they can support pharma companies by providing high-quality containers.
Since the outbreak of the coronavirus pandemic, the Stevanato Group has implemented all safety measures to protect its employees and deployed all available assets to secure its supplies to pharma companies.
“To support the mass vaccination campaign and the ramp-up industrialization needs, we invested in increasing the manufacturing capacity of vials from borosilicate glass,” said Franco Stevanato, CEO of the Stevanato Group.
Gerresheimer said it is also investing more to deliver high-quality products with additional capacity. "We are fully prepared to support the global market demand for potential COVID-19 vaccines with our vials and syringes being produced in our large production facilities in the US, Mexico, Europe and Asia“, said Dietmar Siemssen, CEO Gerresheimer AG.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance